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Background: Fanconi anemia (FA) is a rare inherited genetic syndrome with highly variable clinical manifestations.
Fifteen genetic subtypes of FA have been identified. Traditional complementation tests for grouping studies have
been used generally in FA patients and in stepwise methods to identify the FA type, which can result in
incomplete genetic information from FA patients.
Methods: We diagnosed five pediatric patients with FA based on clinical manifestations, and we performed exome
sequencing of peripheral blood specimens from these patients and their family members. The related sequencing
data were then analyzed by bioinformatics, and the FANC gene mutations identified by exome sequencing were
confirmed by PCR re-sequencing.
Results: Homozygous and compound heterozygous mutations of FANC genes were identified in all of the patients.
The FA subtypes of the patients included FANCA, FANCM and FANCD2. Interestingly, four FA patients harbored
multiple mutations in at least two FA genes, and some of these mutations have not been previously reported.
These patients’ clinical manifestations were vastly different from each other, as were their treatment responses to
androstanazol and prednisone. This finding suggests that heterozygous mutation(s) in FA genes could also have
diverse biological and/or pathophysiological effects on FA patients or FA gene carriers. Interestingly, we were not
able to identify de novo mutations in the genes implicated in DNA repair pathways when the sequencing data of
patients were compared with those of their parents.
Conclusions: Our results indicate that Chinese FA patients and carriers might have higher and more complex
mutation rates in FANC genes than have been conventionally recognized. Testing of the fifteen FANC genes in FA
patients and their family members should be a regular clinical practice to determine the optimal care for the
individual patient, to counsel the family and to obtain a better understanding of FA pathophysiology.
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Fanconi anemia (FA) is a rare inherited genetic syndrome
with diverse clinical manifestations, including develop-
mental defects, short stature, bone marrow failure, and a
high risk of malignancies. The prevalence of FA is 1–5
per 1 million population, and the heterozygous carrier
frequency is estimated at 1 in 300 persons [1]. Ninety per-
cent of the patients experience bone marrow failure by
the age of 40 years old [2]. While androgens and
hematopoietic growth factors are initially effective in
treating FA, the disease has a very poor prognosis that
often leaves bone marrow transplantation as the only op-
tion for a cure, although gene therapy could be a potential
treatment [2]. The clinical manifestations and treatment
responses of FA patients are highly variable, likely due to
multiple factors that are still not quite clear. The FA diag-
nosis is usually confirmed by a positive chromosomal
breakage test (DEB test) and by the subtyping of FA (de-
termination of the complementation group) [3,4].
To date, 15 genetic subtypes of FA have been identified
[5-9]. An FA patient carries either homologous mutations
on two of the same alleles or compound heterozygous
mutations on two different alleles of one FA gene. The
traditional complementation test for group studies has
been used mostly in FA patients, rather than in their fam-
ilies, using a stepwise method [10,11]. If homologous or
compound heterozygous mutations are found in an FA
gene, the subtype of FA is then determined without
knowing whether other FA genes might also be mutated
in the same patient. Thus, while useful, this method could
lead to incomplete genetic information for FA patients.
More complex changes in FA genes in the same patient
are plausible, as different subtypes of FA patients can have
different clinical manifestations. Moreover, the complete
genetic information of FA patients and their families
regarding FA genes could potentially be valuable to the
patients’ prognoses and treatment options, enabling pre-
natal DNA testing, permitting pre-implantation genetic
diagnosis (PGD) for future pregnancies and excluding FA
carriers from bone marrow donation and gene therapy.
To obtain a comprehensive genomic picture of the FA
genes in patients, we captured and sequenced the
exomes of five FA families through peripheral blood
(PB) specimens.
Methods
Diagnosis of FA, patients’ sample collection and genomic
DNA isolation
All of the FA patients were outpatients. The diagnosis of
FA was based on the clinical manifestations of the pa-
tients, MMC testing and single-cell gel electrophoresis
tests using blood lymphocytes. Subsequent studies were
approved by the ethics committee of the Institute of
Hematology, CAMS/PUMC (KT2010072302). A total offive FA patients (designated Fa-001 to Fa-005) and their
parents were recruited for this study and signed in-
formed consent forms. One patient was later identified
as an adopted child of the family (Fa-005). Peripheral
blood (PB) samples from all of the subjects were col-
lected after they were informed of the studies and had
signed an institutional consent form and we also re-
ceived consent from patients to publish the images and
data from these samples. Genomic DNA from the FA
patients and their parents were obtained from mono-
nuclear cells for exome sequencing.
Exome sequencing, data analysis and PCR re-sequencing
The genomic DNA samples were randomly fragmented
by Covaris, and the DNA fragments with base pair peaks
were approximately 150 to 200 bp long. Adapters were
then ligated to both ends of the resulting fragments. The
adapter-ligated templates were purified using Agencourt
AMPure SPRI beads, and fragments with an insert size of
approximately 250 bp were excised. The extracted DNA
was amplified by ligation-mediated PCR (LM-PCR) and
was purified and hybridized to the SureSelect Biotinyl-
ated RNA Library (BAITS, Agilent Inc.) for enrichment.
Hybridized fragments were bound to streptavidin beads,
whereas non-hybridized fragments were washed out after
24 h. Captured LM-PCR products were analyzed using
an Agilent 2100 Bioanalyzer to estimate the magnitude of
their enrichment. Each captured library was then loaded
onto a Hiseq2000 Platform, and massive parallel sequen-
cing was performed for each captured library independ-
ently to ensure that each sample had at least 50-fold
coverage. Raw image files were processed by Illumina
Pipeline software, version 1.6, for base-calling with de-
fault parameters, and the sequences of each individual
were generated as 90 bp paired-end reads. The bioinfor-
matics analyses (Additional file 1: Figure S1) were per-
formed by BGI at Shenzhen, China. The mutations in the
FANC genes identified by exome sequencing were fur-
ther verified by traditional PCR. The SRA accession
number for the Exome-seq data reported in this paper
was SRA067806.
Results
Diagnosis of FA patients
The clinical manifestations (Table 1 and Figure 1), MMC
test results (Additional file 2: Table S1 and Figure 2) and
single-cell gel electrophoresis test results (Additional file
3: Table S2 and Figure 3) are listed. The clinical manifes-
tations of FA were variable but typically included hand
abnormalities (Figure 1-A and B), café au lait spots
(Figure 1-C), short stature, facial feature abnormalities
and bone marrow failure in all of the patients. At an
80 ng/ml concentration of MMC, sample cells from these
five patients showed significantly greater chromosomal
Table 1 Clinical manifestation of FA patients
Fa-001 Fa-002 Fa-003 Fa-004 Fa-005
Sex Male Male Male Female Female
Age at diagnosis
(years)
5 4 7 5 10
History (months) 18 18 84 5 108
Café au lait spots Yes Yes No No Yes
Short stature No Yes No Yes Yes
Hand abnormalities Absence of right hand thumb.
Radial eversion of left hand
thumb.
No Right hand thumb deformity.





Facial features Microcephaly small eyes No No No Microcephaly
Gonads No Hypospadias No No No
Gastrointestinal tract
abnormalities
No No No No Yes
Hematology 1 WBC 2.09 × 109/L 4.27 × 109/L 2.67 × 109/L 6.86 × 109/L 2.78 × 109/L
HGB 32 g/L 93 g/L 78 g/L 106 g/L 57 g/L
PLT 9 × 109/L 30 × 109/L 14 × 109/L 33 × 109/L 42 × 109/L






69 62 59 57 92
Comet cell rates (%)







Blood transfusion 4 U RBC/year 6 U RBC/year No No No
2 dose PLT/year 2 dose PLT/year
Hematology 2 WBC 4.4 × 109/L 3.55 × 109/L 3.03 × 109/L 4.7 × 109/L 3.05 × 109/L
HGB 70 g/L 78 g/L 101 g/L 71 g/L 86 g/L
PLT 16 × 109/L 19 × 109/L 105 × 109/L 25 × 109/L 75 × 109/L
Hematology 1: The first time the patient was admitted to our hospital; Hematology 2: The day after treatment for 24 months ended.
* MMC tests: at an 80 ng/ml concentration of MMC, the percentage of cells with abnormal chromosomes (including chromosome breakage) in the controls was
15% (abnormality cell). The results showed that all of the patients had a greater percentage of abnormality cells than the controls.
** Single-cell gel electrophoresis tests, the comet cell rates of the controls was <10%. The results showed that all of the patients had significantly higher comet cell
rates than the normal controls.
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electrophoresis test, all five patients had significantly
higher comet cell rates than the normal controls. The
karyotypes of these five patients were normal (Additional
file 4: Table S3). These findings supported the diagnosis
of FA in the 5 patients [12].
Exome sequencing data analysis
Exome sequencing was performed by exome capture
with an Agilent SureSelect Human All Exon Kit, the tar-
get region probes of which could cover is 37.2 Mb, and
then was massively parallel paired-end 90 bp read se-
quenced; finally, we obtained 3.64 Gb raw bases on aver-
age for each sample. After mapping to the human
reference genome (NCBI Build 36.3, hg 18), the targetexome sequences had mean coverage of greater than 50-
fold, on average, approximately 80% of the exomes were
covered at least 20-fold, and approximately 90% of the
exomes achieved at least 10-fold, with the coverage rate
of the target region greater than 99%. After an initial
analysis of the sequencing data of all of the FA genes, all
of the identified mutations were re-sequenced for con-
firmation by traditional PCR (Additional file 5: Figure
S2), the MAF of FANC gene SNPs, the SIFT and Poly-
phen prediction of the missense alterations are described
in Additional file 6: Table S4. We found that compound
heterozygous mutations represented the majority of the
mutation types in all of the patients. The types of genetic
aberrations found in this study included single nucleo-
tide substitutions and small (1–8 nucleotides) deletions
Figure 1 Clinical manifestations of representative FA patients. A: Hexadactylism; B: Absence of right hand thumb; C: Café au lait spots.
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included SNPs reported in the NCBI database (the clin-
ical significance of these mutations is unknown) and
some novel mutations (Table 2). According to the muta-
tion results and the results of other experiments, we
identified the subtypes in all of our patients. The FA
subtypes of these patients were FANCA (FA-001 FA-002
and FA-005), FANCM (FA-003) and FANCD2 (FA-004).Figure 2 Mitomycin C chromosome fragility test. Mitomycin C
chromosome fragility test of all of the FA patients and the normal
controls (WT) at various MMC concentrations (count 100 cells).The
patients’ chromosome fragility rates were higher than those of the
controls, which indicated that the patients’ cells were MMC sensitive.FA001 was an FA-A patient with different mutations in
each allele (one inherited from his father and the other
from his mother). He had two mutations in the FANCA
gene, Chr1688389826-32delGGGCTGT and Chr168838
53-54delGG, which were not reported by the Rockefeller
University Fanconi anemia mutation database, but
Chr1688389829-30delCT has been reported 3 times,
Chr16 88385351-54delGAGG has been reported once,Figure 3 Single-cell gel electrophoresis tests. Single-cell gel elec-
trophoresis test of all of the FA patients and the normal controls
(WT) showed that the comet length rates of the patients were
higher than those of the controls.
Table 2 Validated Fanconi gene mutations
Gene Site Mutation Fa-001 Fa-002 Fa-003 Fa-004 Fa-005
F M C F M C F M C F M C C#
FANCA Chr16 88389826-32 -GGGCTGT deletion frameshift √ √
Chr16 88385436* G > A missense A > V √ ※
Chr16 88389853-4 -GG deletion frameshift √ √
Chr16 88385373 -A deletion frameshift √ √
Chr16 88343697* T > C missense S > G √ √
Chr16 88343715 G > A missense R >W √
Chr16 88367267* G > C missense P > A √
Chr16 88343815* A > G intron √
FANCB ChrX 14781120 C > T missense V > I √ ※
FANCM Chr14 44714456 A > G missense I- > V √ √
Chr14 44735218 C > G missense P > A √ √
Chr14 44714339 G > T nonsense N > N √ √
Chr14 44676037 C > T missense S > F √ √
Chr14 44720650 A > G missense I > V √ √
Chr14 44727906 G > A missense R > Q √ √
FANCD1 (BRCA2) Chr13 31809499 C > G missense H > D √ √
Chr13 31804480* A > C missense N > H √ √
Chr13 31809463* A > C missense N > D √ √
Chr13 31871012 A > C 3’-UTR √ √ ※
FANCD2 Chr3 10117949* C > T 3’-UTR √ √
Chr3 10081532* C > T missense P > L √ √
Chr3 10115671* G > A 3’-UTR √ √
FANCI Chr15 87636941* A > G missense I > V √ √
※:homozygous mutation; √: heterozygous mutation; F: father; M: mother; C: child (patient); # Orphan; *SNP.
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in the database, so we diagnosed Fa-001 with the sub-
type of FANCA. Interestingly, the boy patient FA-002
had concomitant homozygous mutations on A, B or D1.
Based on sequencing results, FANCA was a possible
cause of FA in this patient because he had a homozy-
gous mutation. His mother had the same mutation,
while his father did not. DNA sequencing results de-
rived from oral epithelium cells confirmed the Chr16
88385436 position, G > A missense A > V mutation was
indeed the same mutation as in the PB sample, indicat-
ing that the other copy of the mutation was congenital
and did not come from his father. Fa-002 thus had a
possible FA subtype. In contrast, FANCB was on the X
chromosome, so it is possible that patient Fa-002 had a
FANCB subtype. Our PCR re-sequencing confirmed
that patient Fa-002 also has a homozygous mutation in
the FANCD1 (BRCA2) gene in the 3’UTR region (see
Table 2) and this position has been reported as an SNP
site. This 3’UTR mutation is possible to be responsible
for Fa-002’s condition since there were reports that
some mutations in intron and UTR can also causedisease [13]. Thus we performed the complementation
group testing and the patient was confirmed as the
FANCA subtype. FA003 was an FANCM patient with
different mutations in each allele (one from the father
and the other from the mother). FA-004 was an
FANCD2 patient with three different mutations in two
alleles (one from the father and two from the mother).
FA005, an adopted child with no parental genetic infor-
mation, clearly had FANCA, because only three differ-
ent mutations were identified among the FANCA genes.
Surprisingly, we found that, except for patient Fa-005,
all of the patients had multiple mutations in at least 2
FA genes (Table 2), consistent with what Settara C.
Chandrasekharappa reported [13]. Although some mu-
tations we found are the SNPs listed in the database, the
functions of these mutations remain undetermined.
Moreover, some SNPs can also cause disease [14], and
thus we could not exclude that these SNPs are not re-
lated to FA disease. Finally, we were unable to detect
new mutations in genes implicated in DNA repair path-
ways in any FA patients by comparison with their par-
ents’ sequencing data.
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FA is a recessive inherited disease with FA gene muta-
tions that are primarily involved in DNA damage re-
sponse or repair, resulting in genomic instability [13]. Its
complex clinical manifestations are associated with dif-
ferent FA subtypes. Interestingly, the clinical manifesta-
tions can also differ among patients with the same FA
subtype. There is no clear explanation for the relation-
ship between the clinical manifestations of FA patients
and the genetic mutations in their FA genes. To this end,
we performed exome sequencing on PB samples from 5
FA patients and from their parents. Although the sample
size in our study was small, the high frequency of hetero-
zygous mutations in 4 of 5 patients, compared with their
biological parents, suggested that the mutational events
in FA carriers might not occur randomly but rather are
linked. It is probable that a core determinant for some, if
not all, FA genes governs the susceptibility of FA pathway
gene mutations and, thus, of FA clinical manifestations.
In clinical practice, complementation group assignment
and mutational analysis have been routinely used to iden-
tify types of FA patients, with the latter becoming more
prevalent in recent years. The usual strategy for mutation
analysis is to sequence the FANCA, FANCC, FANCE,
FANCG, FANCD2 and other FA genes sequentially until a
subtype of FA is identified [10,11]. The correct subtyping
of FA patients is critical for their prognoses and treatment
because of the clinical variability among subtypes
[1,15,16]. It is conceivable that the specific mutation the-
ory is not always reflected in FA phenotypes because sib-
lings with identical mutations can have different FA
phenotypes [17]. Heterozygous mutations in FA genes
can also have diverse biological and/or pathophysiological
effects on FA patients or FA gene carriers [18-25]. This
finding is also in agreement with our study, in which four
patients had more than one FA mutation gene with, vastly
distinct clinical manifestations and different treatment re-
sponses to androstanazol and prednisone. Furthermore, it
should be noted that synonymous mutations and known
SNPs can also contribute to FA, although each of these
mutations must be studied individually. It will be interest-
ing to determine whether the diverse clinical manifesta-
tions, cancer susceptibilities and biological properties in
the same or different FA subtypes reflect specific combi-
nations of multiple heterozygous FA gene mutations.
Here, we suggest that all FA genes should be subjected to
mutation analysis in clinically diagnosed FA patients and
their parents, in addition to complementation group ana-
lysis, to ascertain the most accurate diagnosis of the FA
subtype, to aid clinicians, as well as families, during gen-
etic counseling process and to advance FA research and
future gene and stem cell therapies.
Although the sample size of our study was small, the
striking number of concomitant mutations in the FAgenes (excluding the SNPs) lead us to believe that se-
quencing of large samples of FA patients and their
families, as well as more detailed biological and func-
tional studies of these samples, are needed to ascertain
the relevance of heterozygous FA gene mutation(s) to
the clinical manifestations and prognoses of FA
patients.
To our surprise, we did not find any new mutations
related to DNA repair pathway genes, especially given
that FA is considered to be a genomic instability dis-
order. There are several possible explanations that could
account for this negative finding. First, new mutations in
DNA repair pathways in HSCs might occur at low fre-
quencies such that those HSCs with new somatic muta-
tions did not have a growth advantage at the time of the
sample collection. Second, some epigenetic mechanisms
other than additional genetic changes, such as muta-
tions, could be involved in the pathogenic process
[26,27]. Third, it is also possible that some of the mu-
tated genes detected by exome-seq might have partici-
pated in DNA repair, but they are currently unknown.
Nevertheless, the sequence analysis of our current data
set suggested that mutations in the FA genes were suffi-
cient for the manifestations of FA patients. Further stud-
ies are needed to ascertain this observation with larger
FA patient pool sizes, to compare the exome sequencing
data of patients before and after the development of
cancer.
Conclusions
In conclusion, although FA subtype mutations define an
FA patient, we found that multiple heterozygous FA
gene mutations inherited from the parents could occur
concomitantly in the same FA patient. The higher muta-
tion rate among FA genes in the same patient also
hinted that a common upstream event could determine
the mutational susceptibility of the FA pathway, and mu-
tations in FA genes alone might be sufficient to initiate
FA in the hematopoietic system. Therefore, our current
report has important implications for the pathogenesis
of FA, as well as for the clinical management (such as
treatment options) of FA patients.
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